ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Tekmira Changes Name, Focuses In On HBV

by Lisa M. Jarvis
July 27, 2015 | APPEARED IN VOLUME 93, ISSUE 30

Tekmira Pharmaceuticals is changing its name to Arbutus Biopharma as it narrows its focus to developing a combination of drugs that can cure chronic hepatitis B virus (HBV) infection. The move follows the recently completed merger with OnCore BioPharma, a Doylestown, Pa.-based firm that added a collection of HBV drug candidates to its pipeline. Tekmira hopes to have four HBV drug candidates in clinical studies by the first half of 2016. Meanwhile, the company is creating an independently financed business unit for all non-HBV assets, including preclinical RNAi drug candidates and related delivery technology. Tekmira is also stopping development of TKM-Ebola, an RNAi-based therapy for the treatment of the deadly infection.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment